Immatics N.V.
HealthcareNASDAQ:IMTX · NASDAQ Capital Market
+$0.32 today
Vol 0.30M · Avg 0.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.6%
avg -37.6%
ROIC
-34.5%
avg -43.6%
ROA
-34.9%
avg -32.7%
Analysis
ROIC is currently the strongest return metric at -34.5% versus its period average of -43.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Harpreet Singh | Chief Executive Officer, MD, Member of Management Board & Executive Director | $996,633.00 | — | 51 | $217,241.00 | 0.16% |
Carsten Reinhardt | Chief Development Officer | — | — | 59 | $0.00 | <0.01% |
Hans-Georg Rammensee | Co-Founder & Member of the Scientific Advisory Board | — | — | — | — | — |
Toni Weinschenk | Co-Founder & Chief Innovation Officer | — | — | 56 | $0.00 | <0.01% |
Venkat Ramanan | Chief Financial Officer | — | — | 56 | $0.00 | <0.01% |
Edward A. Sturchio | General Counsel & Secretary | — | — | — | $0.00 | <0.01% |
Ephraim Hofsäß | Vice President of SEC Reporting & Accounting | — | — | — | — | — |
Steffen Walter | Chief Operations Officer | — | — | 49 | $10,000.00 | <0.01% |
Amie Krause | Chief People Officer | — | — | 53 | $0.00 | <0.01% |
Lauren Schroeder | Vice President of Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +110.8% | +11.4% (8yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +110.8% over three years. Forward estimates point to Revenue at +11.4% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Tourmaline Bio, Inc.
TRML
$1.23B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
Who manages IMTX?
Immatics N.V. (IMTX) lists 10 active executives. The top listed executive is Carsten Reinhardt, Chief Development Officer.
Are IMTX insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.